Pre-clinical studies have demonstrated that the reprogramming of macrophages from M2 to M1 phenotype through blocking the surface markers of macrophages such as CCL2, CCL5, PD-L1, as well as blocking the CD47/SIRPa signaling can effectively activate innate and adaptive immune systems to eliminate cancer cells. This evidence concerns the gene SIRPA and cancer.